Insulet Corporation (PODD) drops after deep earnings analysis
May 7, 202610 min read
Key Takeaway
Insulet Corporation (PODD) delivered a strong first quarter, beating estimates on both EPS and revenue while raising full-year revenue guidance. The business continues to be driven by Omnipod, especially international growth, but the stock sold off sharply as investors focused on valuation, guidance calibration, and a negative post-earnings reaction. For investors, the report confirms solid operating momentum and margin expansion, even if the market is demanding a lower multiple.
Insulet Corporation (PODD) beat first-quarter estimates on both EPS and revenue, raised full-year revenue guidance, and still saw the stock drop hard. That split tells the story: the business delivered another strong Omnipod quarter, but the market focused on valuation reset, guidance calibration, and a post-earnings reaction that turned sharply negative by the next regular-session close.
Key Takeaways
PODD earnings beat on both headline lines. Adjusted EPS was $1.42 versus a $1.19 estimate, while revenue was $761.7M versus a $730M estimate.
The standout segment was international Omnipod. International Omnipod revenue rose 59.4% to $242.9M, while U.S. Omnipod revenue increased 28.3% to $515.6M.
Management raised FY2026 revenue guidance to $3.277B to $3.331B from $3.250B to $3.304B. Q2 revenue guidance of $778.9M to $791.9M was broadly in line with the Street at $787.1M.
CEO Ashley McEvoy framed the quarter around growth momentum, margin expansion, and category leadership in automated insulin delivery. She also highlighted stronger type 2 adoption, improving monthly U.S. trends, and a coming Libre 3 Plus integration.
CFO Flavia Pease guided to roughly 100 basis points of adjusted operating margin expansion for FY2026 and more than 25% adjusted EPS growth, reinforcing that the company is still pushing both growth and profitability.
Analyst reaction was mixed. Consensus remains Buy with 35 Buy ratings, 12 Holds, and 3 Sells, but BTIG cut its price target to $260 from $320 while keeping a Buy rating. Citi had already turned more cautious before the report.
Insulet posted a strong first quarter by the numbers. Revenue came in at $761.7M, up 33.9% year over year, or 30.1% in constant currency. That topped consensus of $730M. Adjusted EPS was $1.42, ahead of the $1.19 estimate and above the prior-year quarter’s $1.02. It also extended a clear streak of beats. Over the last five reported quarters, adjusted EPS came in at $1.42, $1.55, $1.24, $1.17, and $1.02, each above consensus.
The revenue engine remained Omnipod. Total Omnipod revenue reached $758.4M, up 36.9%. Within that, U.S. Omnipod revenue rose 28.3% to $515.6M. International Omnipod revenue climbed 59.4% to $242.9M. That international growth rate stands out because it marks another quarter where overseas expansion did more than add incremental sales. It also strengthened the case that Omnipod is becoming a broader global platform, not just a U.S. success story.
The smaller Drug Delivery business remained a minor piece of the mix. Annual segment data shows Drug Delivery at $34.1M for 2025, down from $38.9M in 2024, while International Omnipod reached $2.6741B, up from $2.0327B. In plain English, the growth story is Omnipod, and especially international Omnipod. That has been true for a while, and this quarter did nothing to change it.
Profitability also improved. Adjusted operating income was $133.5M, and management said adjusted operating margin expanded by 110 basis points year over year. That matters because high-growth medtech names often get graded on whether scale is translating into cleaner economics. Insulet showed that it is. The company also said adjusted EPS growth of about 40% was helped by top-line growth, margin expansion, and a first-quarter share repurchase.
We’re pleased to report a strong start to 2026 with continued growth momentum, robust margin expansion and disciplined execution of the strategic priorities we shared at Investor Day. — Ashley McEvoy, President and CEO, earnings call
Quarterly history adds useful context. Revenue was $760M in the March 2026 quarter, versus $780M in December 2025, $710M in September 2025, $650M in June 2025, and $570M in March 2025. That sequence shows a business still growing at a fast clip, even with normal seasonality from the December quarter. Net income was $90M in the latest quarter, compared with $100M in the prior quarter and $40M in the year-ago March quarter. The trend is not linear every quarter, but the direction is clear.
Guidance was another positive point. Insulet raised FY2026 revenue guidance to $3.277B to $3.331B from $3.250B to $3.304B. Management also reiterated roughly 100 basis points of adjusted operating margin expansion and more than 25% adjusted EPS growth for the full year. Q2 revenue guidance of $778.9M to $791.9M landed near the Street view of $787.1M. So the quarter was not just a beat. It came with a higher full-year revenue range and steady profit targets.
Market Reaction and Analyst Response
The immediate reaction to PODD earnings was positive. Premarket trading on May 6 showed the stock up 4.46% to $175.00 after the company reported the beat and raised guidance. Then the mood changed. By the latest regular-session close, PODD was at $151.28, down 9.70%, with volume of 4.46M shares versus an average of 1.13M. That is not a quiet pullback. That is a heavy-volume reset.
Why would a stock drop after a clean beat and a guidance raise? The facts point to a familiar market pattern. Investors had already been resetting expectations on valuation and growth durability before the print. Several firms had cut targets in April, including Goldman Sachs to $277 from $326, Truist to $315 from $360, Evercore to $240 from $340, and Citi to $230 from $338 when it downgraded the stock to Neutral on April 7. After earnings, BTIG cut its target to $260 from $320 while keeping a Buy rating.
That mix matters. Analysts did not broadly abandon the story, but they did trim the price investors were willing to pay for it. Consensus still leans positive, with 35 Buy ratings, 12 Holds, and 3 Sells. However, the post-earnings tape showed that a good quarter was not enough to overcome a market that wanted either a bigger raise, a cleaner U.S. setup, or simply a cheaper multiple. Stocks can be rude like that.
The next-day style selloff also lines up with one detail in the outlook. Q2 revenue guidance was broadly in line with consensus, not a blowout. For a company that has traded as a premium growth medtech name, in-line near-term guidance after a strong quarter can still trigger selling. The business beat. The stock’s bar was higher.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
CEO Ashley McEvoy used the call to push a simple message: Insulet is still early in a large market, and Omnipod is gaining ground across both geography and patient type. She pointed to 30% total revenue growth, 28% U.S. growth, and 45% international growth in constant currency. More important, she tied that growth to customer starts, retention, pricing, and category expansion in automated insulin delivery.
As a result, we are raising our full year 2026 total company revenue growth guidance from 20% to 22% to 21% to 23%. — Ashley McEvoy, President and CEO, earnings call
McEvoy also addressed a softer point in the quarter: U.S. seasonality. She said the company saw greater-than-normal seasonality tied to annual deductible resets that affected patient co-pays and co-insurance. That helped create a slower start across the U.S. diabetes category. Still, she said month-on-month trends improved through the quarter and into April. That comment matters because it frames the U.S. softness as timing-related rather than structural.
Improving month-on-month trends over the course of the quarter and into April suggests this was a temporary headwind, and we remain confident in our U.S. outlook for the full year. — Ashley McEvoy, President and CEO, earnings call
Strategically, McEvoy highlighted several growth levers. The Libre 3 Plus integration in the U.S. is expected this quarter. She said that opens Omnipod 5 to nearly 450,000 people currently using the Libre 3 Plus sensor. She also pointed to strong type 2 momentum, a 4% net access improvement in the quarter that benefited another 16M lives, and continued expansion in Europe and Canada. Spain is on track for an Omnipod 5 launch in the second half of 2026.
On innovation, the CEO leaned into product cadence. Insulet is launching a second-generation algorithm this quarter, broadening Omnipod Discover, progressing on Omnipod 6 for 2027, and moving its fully closed loop type 2 program forward after enrolling the first participant in the EVOLVE pivotal study. That is the strategic spine of the story: defend leadership now, widen the moat later.
We continue to expect rational and disciplined pricing and rebate behavior. — Ashley McEvoy, President and CEO, earnings call
CFO Flavia Pease handled the financial frame. She joined the call as the executive set to walk through second-quarter and full-year outlook, and management reiterated the key targets tied to her guidance. Those included FY2026 revenue of $3.277B to $3.331B, roughly 100 basis points of adjusted operating margin expansion, and more than 25% adjusted EPS growth. Q2 revenue guidance of $778.9M to $791.9M set the near-term baseline.
We will be discussing Insulet’s first quarter results along with our financial outlook for the second quarter and full year 2026. — Flavia Pease, Chief Financial Officer, earnings call
Analyst Q and A Highlights
The participant list showed analysts from Goldman Sachs, JPMorgan, BofA Securities, Wells Fargo, Piper Sandler, Baird, Raymond James, RBC, and Jefferies on the call. The most revealing debate centered on three themes that management addressed directly in prepared remarks and discussion: U.S. seasonality, international durability, and pricing discipline in the pharmacy channel.
First, analysts pressed on the slower U.S. start and whether it pointed to a deeper demand issue. Management’s defense was direct. McEvoy said deductible resets affected patient out-of-pocket costs and created a temporary drag across the category. She paired that with improving monthly trends through the quarter and into April. That answer did not deny the slowdown. It argued the slowdown was timing-based, not a broken demand engine.
We did experience greater than normal seasonality, which we believe was driven by the annual reset of deductibles impacting patient co-pays and co-insurance. — Ashley McEvoy, President and CEO, earnings call
Second, analysts focused on international growth because 59.4% Omnipod growth overseas is too large to ignore. Management defended that pace with specifics: strong new customer starts, positive price mix from conversion from DASH to Omnipod 5, record starts in the U.K. three years into launch, strong performance in France and Germany, and improved reimbursement in Canada. This matters because it shows international growth was broad-based rather than driven by one market or one-time stocking.
Our international business delivered another standout quarter, driving significant profitable growth and recording our third consecutive quarter of growth above 40%. — Ashley McEvoy, President and CEO, earnings call
Third, analysts pushed on competition and pricing. That is a standard pressure point in diabetes devices, and management did not duck it. McEvoy said the company continues to hold a preferred position in the pharmacy channel and still expects rational pricing and rebate behavior. In other words, competition is rising, but management is not signaling a price war. That distinction matters for margin expectations.
One unexpected topic that stood out was the operational discussion around the March voluntary medical device correction. Management said the team responded quickly and implemented targeted fixes in the relevant manufacturing process. That exchange matters because Insulet’s model depends on producing sophisticated disposable devices at scale. Manufacturing is not a side note here. It is part of the moat.
Manufacturing disposable, sophisticated electromechanical devices at consumer scale and medical quality is a complex process. We continue to believe that our ability to meet the unique manufacturing demand of tubeless AID remains a source of strategic and financial advantage. — Ashley McEvoy, President and CEO, earnings call
Bottom Line
PODD earnings delivered what long-term holders wanted on the operating side: a clean beat, strong Omnipod growth, rising margins, and higher full-year revenue guidance. The stock still drops because the market is repricing the multiple, not because the quarter broke the business.
For investors, the core issue now is simple. If Insulet keeps pairing 30% revenue growth with margin expansion and international scale, the business case remains strong. The market reaction says sentiment is bruised, but the underlying numbers still point to a company gaining share in a large and growing category.
+Did Insulet (PODD) beat earnings estimates in the latest quarter?
Yes. Insulet reported adjusted EPS of $1.42 versus the $1.19 estimate and revenue of $761.7 million versus the $730 million consensus. The company also extended its streak of quarterly EPS beats.
+Why did PODD stock fall after a strong earnings report?
The stock dropped despite the beat because investors appeared to focus on valuation, guidance calibration, and a sharp post-earnings reversal. PODD was up premarket after the report but later fell 9.70% to $151.28 on heavy volume.
+What was the main growth driver for Insulet in Q1?
Omnipod was the clear growth engine, with total Omnipod revenue rising 36.9% to $758.4 million. International Omnipod revenue was especially strong, up 59.4% to $242.9 million, while U.S. Omnipod revenue increased 28.3% to $515.6 million.
+Did Insulet raise its full-year 2026 guidance?
Yes. Insulet raised FY2026 revenue guidance to $3.277 billion to $3.331 billion from $3.250 billion to $3.304 billion. Management also reiterated roughly 100 basis points of adjusted operating margin expansion and more than 25% adjusted EPS growth.
Want the full picture on PODD?
Read the analyst-grade research report — charts, grades, and price targets.
